NCT05918224View on ClinicalTrials.gov

Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Streptococcus salivarius K12

The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.

DRUG

Streptococcus salivarius K12 simulants

Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT05918224 - Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy | Biotech Hunter | Biotech Hunter